Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Eckert & Ziegler BEBIG: Full-Year 2017 Results, return to profitability is been confirmed

Eckert & Ziegler BEBIG
Posted on: 22 Mar 18

Press Release

Regulated Information

Seneffe - Belgium, March 22, 2018 - Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) announced today its consolidated results for the year ending December 31, 2017.

A summary report and a selection of consolidated key figures for the twelve months ending December 31, 2017 can be downloaded at: https://www.bebig.com/home/investors/financial_reports/

Sales for 2017 reached 25.9 million EUR, compared to 24.9 million EUR in 2016, showing an increase of 4%. The main components of this turnover were incomes related to permanent brachytherapy generated by the sales of I-125 radiotherapeutic implants, as well as incomes related to temporary brachytherapy, i.e., HDR equipments (also called "afterloaders") using Co-60 (Cobalt 60) and Ir-192 (Iridium 192) sources.

Earnings before interest and taxes (EBIT) reached 2.2 million EUR in 2017 (2016: 0.5 million EUR) with an EBIT margin of nearly 9% (2016: 2%). Net profit amounted to 1.3 million EUR in 2017 compared to 0.6 million EUR in 2016, showing an increase of 140.3%.

Cash amounted to 5.7 million EUR at the end of December 2017, versus 6.3 million EUR in December 2016. The equity-to-asset ratio stood at 75,3% at the end of December 2017.

About Eckert & Ziegler BEBIG

Contributing to saving lives!

Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treat­ment of cancer using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists. Eckert & Ziegler BEBIG employs approximately 150 people. The company has been listed on the Euronext stock exchange since April 1997.

Contact:

Eckert & Ziegler BEBIG SA
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Eckert & Ziegler BEBIG via GlobeNewswire
HUG#2178031
GlobeNewswire
globenewswire.com

Last updated on: 23/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.